#### India Equity Research | Cement November 14, 2022 **Result Update**

## JK Cement

Refer to important disclosures at the end of this report

# White-cement/wall-putty shine; capacity expansion announced

- JK Cement's Q2FY23 standalone EBITDA declined 16% YoY and 26% QoQ to Rs3bn, standing 7-10% above consensus' and our estimates owing to better-than-expected performance in the wall-putty and white-cement businesses. Blended EBITDA/ton fell 24% YoY/28% QoQ to Rs814 (Emkay Est: Rs750). The Board has approved cement-capacity expansion of 5.5mt and clinker capacity-addition of 0.66mt at a capex of Rs11.6bn (US\$26/ton) over the next two years. Accordingly, Company has revised upward its capex guidance to Rs19bn/Rs14bn vs earlier guidance of Rs17bn and Rs11bn for FY23 and FY24, respectively. Net debt increased by Rs8bn in H1FY23, to Rs29bn as of Sep-22, and Management expects peak net debt of ~Rs35bn by Jun-23. Factoring-in the Q2 beat and higher volume growth with the capacity addition announcement, we increase our EBITDA estimates for FY24-25 by ~5%. We maintain HOLD on the stock, with a revised Sep-23 TP of Rs2,725/share (Rs2,600 earlier). Our DCF-based-TP implies 1-yr forward EV/EBITDA of 11x.
- Results summary: Grey-cement volume (incl. clinker) rose 10% YoY to 3.22mt, in line with our estimate, while grey-cement realization fell 7% QoQ (+5% YoY) to Rs4,838 (Emkay est.: Rs4,904/ton). Premium product sales stood at 9% (+100bps QoQ) of trade sales in Q2FY23. White-cement plus wall-care putty volumes rose 9% YoY and QoQ to 0.42mt, beating our estimate by 8%; realization rose 10% YoY/~3% QoQ to Rs12,540/ton (Emkay est.: Rs11,686/ton). Total cost/ton rose 14% YoY/~2% QoQ to Rs5,064. Consol. EBITDA declined 14% YoY and 24% QoQ to Rs3.1bn, implying that the UAE subsidiary's EBITDA stood at Rs84mn in Q2FY23 vs. EBITDA of Rs7mn/Rs36mn in Q2FY22/Q1FY23. What we liked: Better-than-expected performance in the white-cement and wall-putty businesses; low-cost capex announcement. What we did not like: increase in leverage.
- Earnings-call KTAs: 1) Industry has witnessed price hike of Rs15-20/bag in the South and of Rs10/bag in the West post Sep-22. In the North, the extent of absorption of the Rs10/bag price hike taken in the past couple of days is awaited. 2) Company has already planned for volumes from upcoming capacity in Panna and is hopeful of ramping-up the Panna capacity within 6-9 months. Management maintained grey-cement volume growth guidance of 10% YoY for FY23. To recall, grey-cement volumes increased 12% YoY in H1FY23, which implies 8% volume growth in H2FY23. 3) Fuel mix for the company: Petcoke is 50%, in terms of volume. Fuel cost has gone up by 20% QoQ to Rs2.4/Kcal, and Management expects material benefit from the fuel-cost reduction, likely to be witnessed in Q4FY23. 4) The lead distance stood at 477km in Q2 which the Management expects to decline post the Panna capacity turning fully operational. Road: Rail mix for the quarter stood at 81:19. 4) Project update: 2mt de-bottlenecking capacity at existing plants is likely to be completed by Ma-23. New GU at Ujjain is likely by Mar-24, while that of the grinding unit at Prayagraj, UP is likely in H1FY25. With clinker capacity addition of 0.66mt (Panna clinker line increasing, from 8ktpd to 10ktpd), clinker capacity will increase to 14.5mt, which Management expects can support cement volumes of up to 21mt. 5) Capex guidance revised upward to Rs19bn (vs Rs17bn earlier) for FY23 and Rs14bn (vs Rs11bn earlier) for FY24. Maintenance capex is likely to log at around Rs3bn. Management expects to achieve peak debt of ~Rs35bn by Jun-23.

Please see our sector model portfolio (Emkay Alpha Portfolio): Cement & Building Materials (Page 7)

#### Financial Snapshot (Consolidated)

(Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	66,061	79,908	92,713	1,06,402	1,19,957
EBITDA	15,777	14,824	15,387	20,123	23,136
EBITDA Margin (%)	23.9	18.6	16.6	18.9	19.3
APAT	7,707	6,871	5,906	9,993	12,240
EPS (Rs)	99.7	88.9	76.4	129.3	158.4
EPS (% chg)	56.5	(10.9)	(14.1)	69.2	22.5
ROE (%)	22.8	17.0	12.9	19.0	19.8
P/E (x)	29.5	33.1	38.5	22.7	18.6
EV/EBITDA (x)	15.9	16.4	16.4	12.8	11.1
P/BV (x)	6.1	5.3	4.7	4.0	3.4



Your success is our success

СМР	Target Price
Rs 2,940 as of (November 14, 2022)	Rs 2,725 (▲) 12 months
Rating	Upside
HOLD (∎)	(7.3) %

#### Change in Estimates

onange in Lo	unnau	53		
EPS Chg FY2	3E/FY	′24E ('	%)	(1)/3
Target Price c	hange	e (%)		4.8
Target Period	(Mont	hs)		12
Previous Reco	)			HOLD
Emkay vs Co	nsens	sus		
E	PS E	stimat	tes	
		F	Y23E	FY24E
Emkay			76.4	129.3
Consensus			77.4	107.9
Mean Consen	sus Tl	P (12N	1)	Rs 2,864
Stock Details				
Bloomberg Co				JKCE IN
Face Value (R	s)			10
Shares outsta	nding	(mn)		77
52 Week H/L			3,66	65 / 2,004
M Cap (Rs bn			2	27 / 2.79
Daily Avg Volu	ıme (r	nos.)		1,50,067
Daily Avg Turr	nover	(USD	mn)	5.0
Shareholding	Patte	ern Se	p '22	
Promoters			· · ·	45.8%
FIIs				15.6%
DIIs				21.9%
Public and Oth	ners			16.6%
Price Perform	Janco			
(%)	1M	3M	6M	12M
Absolute	19	11	28	
Rel. to Nifty	11	7	10	
Relative price				()
3600 TRst. 4				% <sub>[</sub> 10
3280				- 0
2960 -				10
2640 -	1 A		N	20
2320 -		<b>b</b> ,	Auf and	30
	<b>N</b> A	W	N	
2000 + Nov-21Jan-22N	/lar-22M	ay-22 Ju	ul-22 Sep	-40 -22Nov-22
JKCE IN		i) —	Rel	to Nifty (RHS)
Source: Bloomb	-			<del>.</del>
This report is sole following person(s production of the	s) are re	sponsil	ble for th	
Dharmesh Sh	ah			
dharmesh.sha +91 22 6612 1	0	nkaygl	obal.co	om
<b>Harshal Milan</b> harshal.mehta			bal.cor	n
	-			

+91 22 6624 2481

Source: Concerns, Entered Besearcheam.emkay@whitemarquesolutions.com use and downloaded at 11/15/2022 07:17 PM

Enkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## **Quarterly Highlights**

#### Exhibit 1: Actual vs. Estimates (Q2FY23) - Standalone

(Bama)	Actual	Estimates		% Variation		Comment
(Rs mn)	Actual	Emkay	Consensus	Emkay	Consensus	Comment
Sales	20,889	20,397	20,763	2.4	0.6	Broadly in-line
EBITDA	2,967	2,710	2,779	9.5	6.8	Owing to better-than-expected performance in the white- cement and wall-putty businesses
Adj PAT	1,248	1,129	1,057	10.5	18.1	Due to higher EBITDA
Volume (mt)	3.6	3.6		0.8		
Blended Realization (Rs/ton)	5,733	5,641		1.6		
EBITDA (Rs/ton)	814	750		8.6		

Source: Company, Bloomberg, Emkay Research

#### Exhibit 2: Quarterly financial highlights (Standalone)

(Rs mn)	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	YoY (%)	QoQ (%)	H1FY22	H1FY23	YoY (%)
Net Sales	18,012	19,028	22,236	21,224	20,889	16.0	(1.6)	34,026	42,113	23.8
Other operating income	344	376	453	441	529	53.9	20.0	666	969	45.6
Revenue	18,355	19,404	22,690	21,664	21,418	16.7	(1.1)	34,692	43,082	24.2
Expenditure	14,805	15,696	18,863	17,663	18,451	24.6	4.5	27,146	36,114	33.0
Total RM	3,198	2,819	4,233	3,439	3,746	17.1	8.9	5,602	7,184	28.3
Power & Fuel	3,437	4,351	4,929	4,856	5,500	60.1	13.3	6,426	10,356	61.2
Freight	3,822	3,834	4,619	4,345	4,352	13.9	0.2	7,168	8,697	21.3
Staff cost	1,298	1,290	1,216	1,430	1,404	8.2	(1.8)	2,536	2,834	11.7
Other expenditure	3,050	3,401	3,866	3,594	3,449	13.1	(4.0)	5,415	7,042	30.1
EBITDA	3,550	3,708	3,827	4,001	2,967	(16.4)	(25.8)	7,546	6,968	(7.7)
Depreciation	687	719	757	899	897	30.6	(0.2)	1,344	1,797	33.7
EBIT	2,863	2,989	3,070	3,102	2,070	(27.7)	(33.3)	6,202	5,172	(16.6)
Other Income	480	264	412	222	228	(52.5)	2.6	753	450	(40.2)
Interest	591	653	689	617	625	5.7	1.3	1,151	1,242	7.9
РВТ	2,752	2,600	2,792	2,707	1,673	(39.2)	(38.2)	5,803	4,380	(24.5)
Total Tax	803	926	630	896	425	(47.2)	(52.6)	1,773	1,320	(25.5)
Adjusted PAT	1,948	1,673	2,163	1,811	1,248	(35.9)	(31.1)	4,031	3,060	(24.1)
Extra ordinary items	(260)	-	(1,300)	-	-			(260)	-	
Reported PAT	1,688	1,673	863	1,811	1,248	(26.0)	(31.1)	3,771	3,060	(18.8)
Adjusted EPS (Rs)	25.2	21.7	28.0	23.4	16.2	(35.9)	(31.1)	52.2	39.6	(24.1)

H1FY23 Margins (%) Q4FY22 Q1FY23 Q2FY23 H1FY22 YoY (%) Q2FY22 Q3FY22 YoY (bps) QoQ (bps) EBITDA 19.3 19.1 16.9 18.5 13.9 (549) (462) 21.8 16.2 (558) 9.7 (465) EBIT 15.6 15.4 13.5 14.3 (593) 17.9 12.0 (587) EBT 7.8 15.0 13.4 12.3 12.5 (718) (468) 16.7 10.2 (656) PAT 5.8 (253) 10.6 8.6 9.5 8.4 (478) 11.6 7.1 (452) Effective Tax rate 29.2 35.6 22.6 33.1 25.4 30.5 30.1

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/15/2022 07:17 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 299 of Singapore.

#### Exhibit 3: Quarterly analysis on per-ton basis (Standalone)

Rs/ton	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	YoY (%)	QoQ (%)	H1FY22	H1FY23	YoY (%)
Grey Cement vols. (mt)	2.9	2.9	3.5	3.2	3.2	9.5	1.5	5.7	6.4	12.2
WC + WP vols. (mt)*	0.4	0.4	0.4	0.4	0.4	8.5	8.8	0.7	0.8	24.3
Total volume (mt)	3.3	3.3	3.9	3.6	3.6	9.4	2.3	6.4	7.2	13.4
Grey Cement realization	4,604	4,844	4,932	5,191	4,838	5.1	(6.8)	4,640	5,013	8.0
White Cement realization	11,455	11,615	12,156	12,230	12,540	9.5	2.5	11,598	12,392	6.8
Blended Realization	5,407	5,728	5,655	5,960	5,733	6.0	(3.8)	5,356	5,845	9.1
Raw Material costs	960	849	1,076	966	1,028	7.1	6.5	882	997	13.1
Power & Fuel costs	1,032	1,310	1,254	1,364	1,510	46.3	10.7	1,012	1,437	42.1
Freight costs	1,147	1,154	1,175	1,220	1,195	4.1	(2.1)	1,128	1,207	7.0
Staff cost	390	388	309	402	385	(1.1)	(4.1)	399	393	(1.5)
Other expenditure	916	1,024	983	1,009	946	3.4	(6.2)	852	977	14.7
Operating cost	4,445	4,725	4,797	4,960	5,064	13.9	2.1	4,273	5,013	17.3
Other operating income	103	113	115	124	145	40.7	17.3	105	135	28.4
Blended EBITDA/ton	1,066	1,116	973	1,124	814	(23.6)	(27.5)	1,188	967	(18.6)

Source: Company, Emkay Research; \*white cement and wall putty

#### Exhibit 4: We have increased our EBITDA estimates by ~2% for FY23 and by 5% for FY24-25

	F	Y23E			FY24E			FY25E	
Y/E Mar (Rs mn)	Old	New	% chg	Old	New	% chg	Old	New	% chg
Revenue	90,129	92,713	2.9	1,02,247	1,06,402	4.1	1,14,586	1,19,957	4.7
EBITDA	15,062	15,387	2.2	19,176	20,123	4.9	22,038	23,136	5.0
PAT	5,960	5,906	(0.9)	9,685	9,993	3.2	11,927	12,240	2.6

Source: Emkay Research

#### Exhibit 5: We maintain HOLD, with revised TP of Rs2,725/share, based on Sep-24E EV/EBITDA

EV/EBITDA valuation, backed by DCF analysis	
Sep-24E EBITDA (Rs bn)	22
Implied EV/EBITDA (x)	11
EV (Rs bn)	240
Net debt (Sep-23E; Rs bn)	30
Equity value (Rs bn)	211
No. of shares (mn)	77
Sep-23 Target Price (Rs/share)	2,725

Source: Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/15/2022 07:17 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### Key Financials (Consolidated)

#### **Income Statement**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	66,061	79,908	92,713	1,06,402	1,19,957
Expenditure	50,284	65,084	77,326	86,279	96,820
EBITDA	15,777	14,824	15,387	20,123	23,136
Depreciation	3,062	3,425	4,290	4,627	4,802
EBIT	12,715	11,399	11,097	15,496	18,335
Other Income	1,130	1,429	1,000	1,050	1,155
Interest expenses	2,528	2,697	2,969	3,227	3,165
PBT	11,317	10,131	9,127	13,319	16,324
Тах	3,675	3,337	3,300	3,404	4,163
Extraordinary Items	(610)	0	0	0	0
Minority Int./Income from Assoc.	66	77	79	79	79
Reported Net Income	7,097	6,871	5,906	9,993	12,240
Adjusted PAT	7,707	6,871	5,906	9,993	12,240

#### Balance Sheet

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Equity share capital	773	773	773	773	773
Reserves & surplus	36,595	42,476	47,496	55,990	66,394
Net worth	37,367	43,249	48,269	56,763	67,167
Minority Interest	(257)	(343)	(428)	(535)	(669)
Loan Funds	34,017	38,549	41,549	41,549	40,049
Net deferred tax liability	5,930	7,383	8,583	9,258	10,081
Total Liabilities	77,057	88,838	97,972	1,07,035	1,16,628
Net block	59,374	65,437	74,298	93,722	1,01,221
Investment	5,578	9,698	9,698	9,698	9,698
Current Assets	28,674	28,574	26,780	27,840	36,688
Cash & bank balance	12,246	3,252	1,194	1,267	8,936
Other Current Assets	0	0	0	0	0
<b>Current liabilities &amp; Provision</b>	21,663	25,192	29,124	30,546	31,800
Net current assets	7,011	3,382	(2,345)	(2,706)	4,888
Misc. exp	0	0	0	0	0
Total Assets	77,057	88,838	97,972	1,07,035	1,16,628

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
PBT (Ex-Other income) (NI+Dep)	9,643	8,779	8,207	12,348	15,249
Other Non-Cash items	600	908	1,200	675	823
Chg in working cap	1,531	(5,366)	3,669	434	75
Operating Cashflow	13,689	7,107	17,036	17,907	19,950
Capital expenditure	(6,680)	(14,386)	(19,000)	(14,000)	(6,750)
Free Cash Flow	7,008	(7,279)	(1,964)	3,907	13,200
Investments	(5,128)	(4,449)	0	0	0
Other Investing Cash Flow	0	0	0	0	0
Investing Cashflow	(10,679)	(17,406)	(18,000)	(12,950)	(5,595)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	4,324	4,532	3,000	0	(1,500)
Dividend paid (incl tax)	(1,159)	(1,159)	(886)	(1,499)	(1,836)
Other Financing Cash Flow	2,255	629	(237)	(158)	(184)
Financing Cashflow	2,892	1,305	(1,093)	(4,884)	(6,686)
Net chg in cash	5,902	(8,995)	(2,057)	73	7,669
Opening cash position	6,345	12,246	3,252	1,194	1,267
Closing cash position	12,246	3,252	1,194	1,267	8,936

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/15/2022 07:17 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Profitability (%)	FY21	FY22	FY23E	FY24E	FY25E
EBITDA Margin	23.9	18.6	16.6	18.9	19.3
EBIT Margin	19.2	14.3	12.0	14.6	15.3
Effective Tax Rate	32.5	32.9	36.2	25.6	25.5
Net Margin	11.6	8.5	6.3	9.3	10.1
ROCE	19.6	15.5	13.0	16.1	17.4
ROE	22.8	17.0	12.9	19.0	19.8
RoIC	16.2	12.8	10.4	14.4	14.6
Per Share Data (Rs)	FY21	FY22	FY23E	FY24E	FY25E
EPS	99.7	88.9	76.4	129.3	158.4
CEPS	139.4	133.2	132.0	189.2	220.5
BVPS	483.6	559.7	624.7	734.6	869.3
DPS	15.0	15.0	11.5	19.4	23.8
Valuations (x)	FY21	FY22	FY23E	FY24E	FY25E
PER	29.5	33.1	38.5	22.7	18.6
P/CEPS	21.1	22.1	22.3	15.5	13.3
P/BV	6.1	5.3	4.7	4.0	3.4
EV / Sales	3.7	3.2	2.8	2.5	2.1
EV / EBITDA	15.9	16.4	16.4	12.8	11.1
Dividend Yield (%)	0.5	0.5	0.4	0.7	0.8
Cooring Datia (v)	EV24	EV22	EVO2E	EV24E	EVOE
Gearing Ratio (x)	FY21	FY22	FY23E	FY24E	FY25E
Net Debt/ Equity Net Debt/EBIDTA	0.4	0.6 1.7	0.6 2.0	0.5 1.5	0.3
Working Cap Cycle (days)	(28.9)	0.6	(13.9)	(13.6)	(12.3
	(20.9)	0.0	(13.9)	(13.0)	(12.5
Growth (%)	FY21	FY22	FY23E	FY24E	FY25
Revenue	13.9	21.0	16.0	14.8	12.
EBITDA	30.0	(6.0)	3.8	30.8	15.0
EBIT	37.4	(10.3)	(2.7)	39.6	18.3
PAT	44.1	(3.2)	(14.1)	69.2	22.5
Quarterly (Rs mn)	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY2
Revenue	18,355	19,404	22,690	21,664	21,418
EBITDA	3,550	3,708	3,827	4,001	2,96
EBITDA Margin (%)	19.3	19.1	16.9	18.5	13.9
PAT	1,688	1,673	863	1,811	1,24
EPS (Rs)	21.8	21.7	11.2	23.4	16.2
EF3 (KS)	-			-	-
Source: Company, Emkay Research					
	Sep-21	Dec-21	Mar-22	Jun-22	Sep-2
Source: Company, Emkay Research	<b>Sep-21</b> 57.6	<b>Dec-21</b> 51.5	<b>Mar-22</b> 45.8	<b>Jun-22</b> 45.8	-
Source: Company, Emkay Research Shareholding Pattern (%)	-				45.8
Source: Company, Emkay Research Shareholding Pattern (%) Promoters	57.6	51.5	45.8	45.8	<b>Sep-22</b> 45.8 15.6 21.9

Source: Capitaline

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/15/2022 07:17 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### RECOMMENDATION HISTORY (Rs/share)

Date	Closing Price	ТР	Period	Rating	Analyst
05-Nov-22	2,780	2,600	12m	Hold	Dharmesh Shah
04-Oct-22	2,589	2,600	12m	Hold	Dharmesh Shah
04-Sep-22	2,705	2,600	12m	Hold	Dharmesh Shah
16-Aug-22	2,653	2,600	12m	Hold	Dharmesh Shah
04-Jul-22	2,197	2,360	12m	Hold	Dharmesh Shah
28-Jun-22	2,100	2,360	12m	Hold	Dharmesh Shah
23-May-22	2,436	2,700	12m	Hold	Dharmesh Shah
16-Mar-22	2,486	2,700	12m	Hold	Dharmesh Shah
11-Mar-22	2,296	3,150	12m	Hold	Dharmesh Shah
06-Mar-22	2,640	3,150	12m	Hold	Dharmesh Shah
08-Feb-22	3,306	3,150	12m	Hold	Dharmesh Shah
31-Dec-21	3,399	3,300	12m	Hold	Dharmesh Shah
02-Dec-21	3,333	3,300	12m	Hold	Dharmesh Shah
16-Nov-21	3,518	3,300	12m	Hold	Dharmesh Shah
05-Sep-21	3,500	3,100	12m	Hold	Dharmesh Shah
17-Aug-21	3,192	3,100	12m	Hold	Dharmesh Shah
13-Jun-21	2,851	3,000	12m	Hold	Dharmesh Shah
06-Jun-21	2,838	3,000	12m	Hold	Dharmesh Shah
28-Apr-21	2,789	3,000	12m	Hold	Dharmesh Shah

**RECOMMENDATION HISTORY (Rs/share)** 



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/15/2022 07:17 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## Emkay Alpha Portfolio – Cement & Building Materials

#### EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight based on Current NAV	Change vs last published EAP (bps)
Cement & Building Materials	2.20	2.20	0%	0	100.00	
ACC	0.19	0.19	0%	0	8.43	0
Ambuja Cements	0.38	0.37	-2%	-1	16.76	0
Birla Corporation	0.00	0.00	NA	0	0.00	0
Dalmia Bharat	0.12	0.06	-48%	-6	2.91	0
Grasim Industries*	0.59	0.59	0%	0	26.75	0
JK Cement	0.00	0.04	NA	4	2.03	0
Ramco Cements	0.00	0.00	NA	0	0.00	0
Shree Cements	0.20	0.20	0%	0	9.29	0
Star Cement	0.00	0.00	NA	0	0.00	0
Ultratech Cement	0.72	0.75	3%	2	33.83	0
Cash	0.00	0.00	NA	0	0.00	0

Source: Emkay Research

High Conviction/Strong Over Weight


#### Sector portfolio NAV

	Base					Latest
	1-Apr-19	12-Nov-21	13-May-22	12-Aug-22	11-Oct-22	11-Nov-22
EAP - Cement & Building Materials	100.0	192.9	150.6	159.9	161.0	175.0
BSE200 Neutral Weighted Portfolio (ETF)	100.0	186.0	144.0	153.1	155.6	169.2
*Performance measurement base date	e 1 <sup>st</sup> April 2019					

Source: Emkay Research

#### Price Performance (%)

	1m	3m	6m	12m
EAP - Cement & Building Materials	8.7%	9.4%	16.2%	-9.3%
BSE200 Neutral Weighted Portfolio (ETF)	8.7%	10.5%	17.4%	-9.0%
Source: Emkay Research				



Source: Emkay Research

#### Please see our model portfolio (Emkay Alpha Portfolio): Nifty

#### Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/15/2022 07:17 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.



#### Analyst: Dharmesh Shah

#### **Contact Details**

dharmesh.shah@emkayglobal.com +91 22 6612 1255

#### Sector

**Cement & Building Materials** 

#### Analyst bio

Dharmesh is a CA and has around 10 years of experience in equity research. His team currently covers ten stocks in cement sector.

#### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.		
BUY	Over 15%		
HOLD	Between -5% to 15%		
SELL	Below -5%		

Completed Date: 15 Nov 2022 01:06:58 (SGT) Dissemination Date: 15 Nov 2022 01:07:58 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/15/2022 07:17 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMIKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of November 14, 2022
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of November 14, 2022.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 14, 2022
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services form securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the November 14, 2022

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/15/2022 07:17 PM

RESTRICTIONS ON I	
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

#### Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/15/2022 07:17 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.